Cargando…

Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk

Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of...

Descripción completa

Detalles Bibliográficos
Autores principales: König, Laila, Haering, Peter, Lang, Clemens, Splinter, Mona, von Nettelbladt, Bastian, Weykamp, Fabian, Hoegen, Philipp, Lischalk, Jonathan W., Herfarth, Klaus, Debus, Jürgen, Hörner-Rieber, Juliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358352/
https://www.ncbi.nlm.nih.gov/pubmed/32733794
http://dx.doi.org/10.3389/fonc.2020.00989
_version_ 1783558835032555520
author König, Laila
Haering, Peter
Lang, Clemens
Splinter, Mona
von Nettelbladt, Bastian
Weykamp, Fabian
Hoegen, Philipp
Lischalk, Jonathan W.
Herfarth, Klaus
Debus, Jürgen
Hörner-Rieber, Juliane
author_facet König, Laila
Haering, Peter
Lang, Clemens
Splinter, Mona
von Nettelbladt, Bastian
Weykamp, Fabian
Hoegen, Philipp
Lischalk, Jonathan W.
Herfarth, Klaus
Debus, Jürgen
Hörner-Rieber, Juliane
author_sort König, Laila
collection PubMed
description Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of randomizing patients between modalities. The objective of the current study is to calculate the risk for secondary malignancies following PRT and photon-based intensity-modulated radiotherapy (IMRT). Materials and Methods: Twenty-three patients (16 female and seven male), previously treated with active scanning PRT for malignant mediastinal lymphoma at Heidelberg Ion Beam Therapy Center, were retrospectively re-planned using helical photon IMRT. The risk for radiation-induced secondary malignancies was estimated and evaluated using two distinct prediction models (1–4). Results: According to the Dasu model, the median absolute total risk for tumor induction following IMRT was 4.4% (range, 3.3–5.8%), 9.9% (range, 2.0–27.6%), and 1.0% (range, 0.5–1.5%) for lung, breast, and esophageal cancer, respectively. For PRT, it was significantly lower for the aforementioned organs at 1.6% (range, 0.7–2.1%), 4.5% (range, 0.0–15.5), and 0.8% (range, 0.0–1.6%), respectively (p ≤ 0.01). The mortality risk from secondary malignancies was also significantly reduced for PRT relative to IMRT at 1.1 vs. 3.1% (p ≤ 0.001), 0.9 vs. 1.9% (p ≤ 0.001), and 0.7 vs. 1.0% (p ≤ 0.001) for lung, breast, and esophageal tumors, respectively. Using the Schneider model, a significant risk reduction of 54.4% (range, 32.2–84.0%), 56.4% (range, 16.0–99.4%), and 24.4% (range, 0.0–99.0%) was seen for secondary lung, breast, and esophageal malignancies, favoring PRT vs. X-ray-based IMRT (p ≤ 0.01). Conclusion: Based on the two prediction models, PRT for malignant mediastinal lymphoma is expected to reduce the risk for radiation-induced secondary malignancies compared with the X-ray-based IMRT. The young age and the long natural history of patients diagnosed with mediastinal lymphoma predisposes them to a high risk of secondary malignancies following curative radiotherapy treatment and, as a consequence, potentially reducing this risk by utilizing advanced radiation therapy techniques such as PRT should be considered.
format Online
Article
Text
id pubmed-7358352
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73583522020-07-29 Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk König, Laila Haering, Peter Lang, Clemens Splinter, Mona von Nettelbladt, Bastian Weykamp, Fabian Hoegen, Philipp Lischalk, Jonathan W. Herfarth, Klaus Debus, Jürgen Hörner-Rieber, Juliane Front Oncol Oncology Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to a decreased integral dose to the surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long-term follow-up and the ethical complexities of randomizing patients between modalities. The objective of the current study is to calculate the risk for secondary malignancies following PRT and photon-based intensity-modulated radiotherapy (IMRT). Materials and Methods: Twenty-three patients (16 female and seven male), previously treated with active scanning PRT for malignant mediastinal lymphoma at Heidelberg Ion Beam Therapy Center, were retrospectively re-planned using helical photon IMRT. The risk for radiation-induced secondary malignancies was estimated and evaluated using two distinct prediction models (1–4). Results: According to the Dasu model, the median absolute total risk for tumor induction following IMRT was 4.4% (range, 3.3–5.8%), 9.9% (range, 2.0–27.6%), and 1.0% (range, 0.5–1.5%) for lung, breast, and esophageal cancer, respectively. For PRT, it was significantly lower for the aforementioned organs at 1.6% (range, 0.7–2.1%), 4.5% (range, 0.0–15.5), and 0.8% (range, 0.0–1.6%), respectively (p ≤ 0.01). The mortality risk from secondary malignancies was also significantly reduced for PRT relative to IMRT at 1.1 vs. 3.1% (p ≤ 0.001), 0.9 vs. 1.9% (p ≤ 0.001), and 0.7 vs. 1.0% (p ≤ 0.001) for lung, breast, and esophageal tumors, respectively. Using the Schneider model, a significant risk reduction of 54.4% (range, 32.2–84.0%), 56.4% (range, 16.0–99.4%), and 24.4% (range, 0.0–99.0%) was seen for secondary lung, breast, and esophageal malignancies, favoring PRT vs. X-ray-based IMRT (p ≤ 0.01). Conclusion: Based on the two prediction models, PRT for malignant mediastinal lymphoma is expected to reduce the risk for radiation-induced secondary malignancies compared with the X-ray-based IMRT. The young age and the long natural history of patients diagnosed with mediastinal lymphoma predisposes them to a high risk of secondary malignancies following curative radiotherapy treatment and, as a consequence, potentially reducing this risk by utilizing advanced radiation therapy techniques such as PRT should be considered. Frontiers Media S.A. 2020-07-07 /pmc/articles/PMC7358352/ /pubmed/32733794 http://dx.doi.org/10.3389/fonc.2020.00989 Text en Copyright © 2020 König, Haering, Lang, Splinter, von Nettelbladt, Weykamp, Hoegen, Lischalk, Herfarth, Debus and Hörner-Rieber. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
König, Laila
Haering, Peter
Lang, Clemens
Splinter, Mona
von Nettelbladt, Bastian
Weykamp, Fabian
Hoegen, Philipp
Lischalk, Jonathan W.
Herfarth, Klaus
Debus, Jürgen
Hörner-Rieber, Juliane
Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title_full Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title_fullStr Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title_full_unstemmed Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title_short Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
title_sort secondary malignancy risk following proton vs. x-ray treatment of mediastinal malignant lymphoma: a comparative modeling study of thoracic organ-specific cancer risk
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358352/
https://www.ncbi.nlm.nih.gov/pubmed/32733794
http://dx.doi.org/10.3389/fonc.2020.00989
work_keys_str_mv AT koniglaila secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT haeringpeter secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT langclemens secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT splintermona secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT vonnettelbladtbastian secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT weykampfabian secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT hoegenphilipp secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT lischalkjonathanw secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT herfarthklaus secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT debusjurgen secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk
AT hornerrieberjuliane secondarymalignancyriskfollowingprotonvsxraytreatmentofmediastinalmalignantlymphomaacomparativemodelingstudyofthoracicorganspecificcancerrisk